Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Elena Liew"'
Autor:
Elena Liew, Carolyn Owen
Publikováno v:
Haematologica, Vol 96, Iss 10 (2011)
Familial cases of myelodysplastic syndromes are rare, but are immensely valuable for the investigation of the molecular pathogenesis of myelodysplasia in general. The best-characterized familial myelodysplastic syndrome is that of familial platelet d
Externí odkaz:
https://doaj.org/article/d8ad504d865748b4a085098453d8787e
Autor:
Maria Agustina Perusini, Eshetu G. Atenafu, Donna L. Forrest, Bence-Bruckler Isabelle, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy L. Stockley, Jeffrey H. Lipton, Brian Leber, Dennis Dong Hwan Kim
Publikováno v:
Blood. 140:6778-6779
Autor:
Kurt Ebeling, Peng Wang, Elena Liew, Nancy Zhu, Mark Hnatiuk, Minakshi S. Taparia, Marlene Hamilton, Joseph Brandwein
Publikováno v:
Blood. 140:11636-11637
Autor:
Igor Novitzky-Basso, Elena Liew, Eshetu G. Atenafu, Lambert Busque, Pierre Laneuville, Kristjan Paulson, Dennis Dong Hwan Kim, Mary-Margaret Keating, Isabelle Bence-Bruckler, Robert Delage, Suzanne Kamel-Reid, Tracy Stockley, Jeffrey H. Lipton, Donna L. Forrest, Brian Leber, Taehyung S Kim, Lynn Savoie, Anargyros Xenocostas
Publikováno v:
British Journal of Haematology. 193:779-791
Although total duration of tyrosine kinase inhibitor (TKI) therapy and of molecular response at 4 log reduction or deeper (MR4) correlates with treatment-free remission (TFR) success after TKI discontinuation, the optimal cut-off values of the durati
Autor:
Dennis Dong Hwan Kim, Lambert Busque, Suzanne Kamel-Reid, Elena Liew, Anargyros Xenocostas, Igor Novitzky Basso, Mary-Margaret Keating, Lynn Savoie, Taehyung Simon Kim, Brian Leber, Tracy Stockley, Robert Delage, Donna L. Forrest, Pierre Laneuville, Kristjan Paulson, Jeffrey H. Lipton, Isabelle Bence-Bruckler, Eshetu G. Atenafu
Publikováno v:
British journal of haematologyReferences. 196(1)
The doubling time (DT) of the BCR-ABL1 quantitative polymerase chain reaction (qPCR) transcript level reflects the re-growing fraction of leukaemic cells after discontinuation of tyrosine kinase inhibitor (TKI). The present study analyzed monthly DT
Autor:
Jennifer Jupp, Deonne Dersch-Mills, Elena Liew, Sunita Ghosh, Kareem Jamani, Catherine Leyshon, Lynn Savoie, Chen-En Ma, Nikki Blosser
Publikováno v:
Leukemia research. 111
While second generation tyrosine kinase inhibitors (2GTKIs) are highly effective therapies for chronic myeloid leukemia (CML), a significant minority of patients who initiate a 2GTKI will require a switch to an alternative TKI. The long-term outcomes
Autor:
Minakshi Taparia, Nancy Zhu, Aniket Bankar, Marlene Hamilton, Joseph Brandwein, Jeffrey M. Patterson, Tiffany Van Slyke, Elena Liew, Lauren Bolster, Lalit Saini, Mohammad Karkhaneh, Cynthia Wu, Darren Hallett
Publikováno v:
American Journal of Hematology. 96
Autor:
Igor Novitzky-Basso, Donna L. Forrest, Mary-Margaret Keating, Tracy Stockley, Lynn Savoie, Lambert Busque, Anargyros Xenocostas, Elena Liew, Isabelle Bence-Bruckler, Pierre Laneuville, Jeffrey H. Lipton, Kristjan Paulson, Robert Delage, Eshetu G. Atenafu, Suzanne Kamel-Reid, Taehyung Kim, Brian Leber, Dennis Dong Hwan Kim
Publikováno v:
Blood. 136:40-41
Background: The Canadian tyrosine kinase inhibitor (TKI) discontinuation trial, named "Treatment Free Remission Accomplished By Dasatinib " (NCT#02268370), has reported 56.8% molecular relapse-free survival (mRFS) rate at 12 months after imatinib (IM
Autor:
Lynn Savoie, Elena Liew, Lambert Busque, Georgina S. Daher-Reyes, Donna L. Forrest, Robert Delage, Suzanne Kamel-Reid, Mary-Margaret Keating, Pierre Laneuville, Isabelle Bence-Bruckler, Kristjan Paulson, Brian Leber, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Anargyros Xenocostas
Publikováno v:
Blood. 134:1653-1653
Introduction: Tyrosine kinase inhibitor (TKI) therapy can result in the adverse events of prolonged anemia, thrombocytopenia and/or leukopenia via c-kit blockade in hematopoietic stem cells. Previous studies have reported that even low-grade adverse
Autor:
Dennis Dong Hwan Kim, Pierre Laneuville, Brian Leber, Suzanne Kamel-Reid, Donna L. Forrest, Kristjan Paulson, Lambert Busque, Mary-Margaret Keating, Isabelle Bence-Bruckler, Jeffrey H. Lipton, Anargyros Xenocostas, Elena Liew, Robert Delage, Lynn Savoie
Publikováno v:
Blood. 134:1644-1644
Introduction: The Canadian trial entitled "Treatment Free Remission Accomplished By Dasatinib" (BMS CA180543, NCT#02268370) is ongoing since Jan 2015, and has completed accrual of 131 patients. The study was designed to determine if using dasatinib (